Table 2.
Baseline characteristics of 4304 patients after propensity score match according to treatment
| RT (N = 2152) | RP (N = 2152) | P value | |
|---|---|---|---|
| Age | 76.88 ± 2.30 | 76.89 ± 2.51 | 0.8791 |
| PSA | 79.51 ± 92.88 | 75.11 ± 88.92 | 0.1121 |
| Year of diagnosis | <0.0001 | ||
| 2004 | 226 (10.50%) | 165 (7.67%) | |
| 2005 | 186 (8.60%) | 132 (6.13%) | |
| 2006 | 189 (8.78%) | 156 (7.25) | |
| 2007 | 195 (9.06%) | 205 (9.53%) | |
| 2008 | 204 (9.48%) | 166 (7.71%) | |
| 2009 | 189 (8.78%) | 190 (8.83%) | |
| 2010 | 200 (9.29%) | 222 (10.32%) | |
| 2011 | 200 (9.29%) | 215 (9.99) | |
| 2012 | 139 (6.46%) | 161 (7.48%) | |
| 2013 | 148 (6.88%) | 193 (8.97%) | |
| 2014 | 127 (5.90%) | 158 (7.34%) | |
| 2015 | 149 (6.92%) | 189 (8.78%) | |
| Marital status | 0.0604 | ||
| Married | 1728 (80.3%) | 1679 (78%) | |
| Single | 103 (4.8%) | 106 (4.9%) | |
| Divorced/widowed | 202 (9.4%) | 256 (11.9%) | |
| Unknown | 119 (5.5%) | 111 (5.2%) | |
| Race | 0.0083 | ||
| White | 1892 (87.9%) | 1867 (86.8%) | |
| Black | 137 (6.4%) | 113 (5.3%) | |
| Other | 105 (4.9%) | 154 (7.2%) | |
| Unknown | 18 (0.8%) | 18 (0.8%) | |
| GS | <0.0001 | ||
| ≤6 | 324 (15.1%) | 346 (16.1%) | |
| 7 | 487 (22.6%) | 522 (24.3%) | |
| ≥8 | 277 (12.9%) | 115 (5.3%) | |
| Unknown | 1064 (49.4%) | 1169 (54.3%) | |
| Region | <0.0001 | ||
| East | 744 (34.6%) | 452 (21%) | |
| Pacific | 1006 (46.7%) | 1413 (65.7%) | |
| North | 319 (14.8%) | 134 (6.2%) | |
| Other(Alaska and Southwest) | 83 (3.9%) | 153 (7.1%) |
Abbreviations: GS, Gleason score; PSA, prostate specific antigen; RT, radiation therapy; RP, radical prostatectomy.